Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase IIIb, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-stage Small Cell Lung Cancer - MAURIS

    Summary
    EudraCT number
    2019-001146-17
    Trial protocol
    IT  
    Global end of trial date
    13 Jul 2023

    Results information
    Results version number
    v1(current)
    This version publication date
    08 Aug 2024
    First version publication date
    08 Aug 2024
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    ML41118
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04028050
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Hoffmann-La Roche AG
    Sponsor organisation address
    Grenzacherstrasse 124, Basel, Switzerland, CH-4070
    Public contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
    Scientific contact
    F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    13 Jul 2023
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    13 Jul 2023
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the safety of atezolizumab in combination with carboplatin plus etoposide in patients with untreated extensive-stage small cell lung cancer (ES SCLC).
    Protection of trial subjects
    All study subjects were required to read and sign an Informed Consent Form.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    09 Aug 2019
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Italy: 155
    Worldwide total number of subjects
    155
    EEA total number of subjects
    155
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    72
    From 65 to 84 years
    83
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    The study was conducted at 25 locations in Italy.

    Pre-assignment
    Screening details
    A total of 155 participants were enrolled.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    Atezolizumab + Carboplatin + Etoposide
    Arm description
    Participants who received treatment until disease progression per RECIST v1.1, unacceptable toxicity, or symptomatic deterioration attributed to disease progression as determined by the investigator.
    Arm type
    Experimental

    Investigational medicinal product name
    Tecentriq
    Investigational medicinal product code
    Other name
    Atezolizumab RO5541267
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Fixed dose of 1200mg Q3W (1200 mg on Day 1 of each 21-day cycle during both the induction and the maintenance phase)

    Investigational medicinal product name
    Etoposide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    100 mg per square meter of body-surface area, administered intravenously on days 1 through 3 of each cycle. On Days 2 and 3, patients received etoposide alone.

    Investigational medicinal product name
    Carboplatino
    Investigational medicinal product code
    Other name
    Carboplatin
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    AUC 5mg per millilitre per minute, administered intravenously.

    Number of subjects in period 1
    Atezolizumab + Carboplatin + Etoposide
    Started
    155
    Received at >1 dose of study treatment
    154
    Completed Induction Phase
    120
    Completed Maintenance Phase
    136
    Completed
    19
    Not completed
    136
         Adverse event, serious fatal
    1
         Consent withdrawn by subject
    7
         Physician Decision
    2
         Death
    118
         Progressive Disease
    1
         Unknown
    1
         Lost to follow-up
    6

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Atezolizumab + Carboplatin + Etoposide
    Reporting group description
    Participants who received treatment until disease progression per RECIST v1.1, unacceptable toxicity, or symptomatic deterioration attributed to disease progression as determined by the investigator.

    Reporting group values
    Atezolizumab + Carboplatin + Etoposide Total
    Number of subjects
    155 155
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    72 72
        From 65-84 years
    83 83
        85 years and over
    0 0
    Age Continuous
    Units: Number
        arithmetic mean (standard deviation)
    65.1 ( 9.05 ) -
    Sex: Female, Male
    Units:
        Female
    60 60
        Male
    95 95
    Ethnicity (NIH/OMB)
    Units: Subjects
        Hispanic or Latino
    2 2
        Not Hispanic or Latino
    153 153
        Unknown or Not Reported
    0 0
    Race (NIH/OMB)
    Units: Subjects
        American Indian or Alaska Native
    0 0
        Asian
    0 0
        Native Hawaiian or Other Pacific Islander
    0 0
        Black or African American
    0 0
        White
    154 154
        More than one race
    0 0
        Unknown or Not Reported
    1 1

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Atezolizumab + Carboplatin + Etoposide
    Reporting group description
    Participants who received treatment until disease progression per RECIST v1.1, unacceptable toxicity, or symptomatic deterioration attributed to disease progression as determined by the investigator.

    Primary: Incidence of serious adverse events (SAEs) related to atezolizumab in combination with carboplatin plus etoposide treatment.

    Close Top of page
    End point title
    Incidence of serious adverse events (SAEs) related to atezolizumab in combination with carboplatin plus etoposide treatment. [1]
    End point description
    Percentage of participants that experienced a serious adverse events (SAE) related to treatment.
    End point type
    Primary
    End point timeframe
    From first dose of study treatment to 4 weeks after last dose of study treatment (3 years, 11 months).
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There was no hypothesis testing planned for this outcome measure. The analysis is descriptive in nature.
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    154
    Units: Percentage of participants
        number (not applicable)
    21.4
    No statistical analyses for this end point

    Primary: Incidence of Serious and Non-Serious Immune Mediated Adverse Events (imAEs)

    Close Top of page
    End point title
    Incidence of Serious and Non-Serious Immune Mediated Adverse Events (imAEs) [2]
    End point description
    Incidence of serious and non-serious immune-mediated adverse events (imAEs) related to treatment.
    End point type
    Primary
    End point timeframe
    From first dose of study treatment to 4 weeks after last dose of study treatment (3 years, 11 months).
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: There was no hypothesis testing planned for this outcome measure. The analysis is descriptive in nature.
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    154 [3]
    Units: Percentage of participants
        number (not applicable)
    28.6
    Notes
    [3] - 1 participant withdrew before starting treatment
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) Rate at 1 Year

    Close Top of page
    End point title
    Overall Survival (OS) Rate at 1 Year
    End point description
    Overall Survival (OS) at 1 year, defined as the percentage of participants remaining alive at 1 year after initiation of study treatment.
    End point type
    Secondary
    End point timeframe
    From initiation of study treatment to 1 Year (12 months).
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Percentage of participants
        number (confidence interval 95%)
    45.5 (37.2 to 54.0)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) Rate at 2 Years

    Close Top of page
    End point title
    Overall Survival (OS) Rate at 2 Years
    End point description
    OS at 2 years, defined as the percentage of participants remaining alive at 2 years after initiation of study treatment.
    End point type
    Secondary
    End point timeframe
    2 Years
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Percentage of participants
        number (confidence interval 95%)
    17.1 (11.3 to 24.4)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS) Rate at 3 Years

    Close Top of page
    End point title
    Overall Survival (OS) Rate at 3 Years
    End point description
    OS at 3 years, defined as the percentage of participants remaining alive at 3 years after initiation of study treatment.
    End point type
    Secondary
    End point timeframe
    3 Years
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Percentage of participants
        number (confidence interval 95%)
    14.5 (9.1 to 21.5)
    No statistical analyses for this end point

    Secondary: Overall Survival (OS)

    Close Top of page
    End point title
    Overall Survival (OS)
    End point description
    Overall Survival (OS), defined as the time from initiation of study treatment to death from any cause.
    End point type
    Secondary
    End point timeframe
    Overall Survival (OS) is defined as the time (in months) from initiation of study treatment to death from any cause. (3 years, 11 months)
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Months
        median (confidence interval 95%)
    10.6 (9.8 to 13.7)
    No statistical analyses for this end point

    Secondary: Progression-Free Survival (PFS)

    Close Top of page
    End point title
    Progression-Free Survival (PFS)
    End point description
    Progression-Free Survival (PFS), is defined as the time (in months) from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first. PFS will be calculated based on disease status evaluated by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
    End point type
    Secondary
    End point timeframe
    From from initiation of study treatment to the first occurrence of disease progression or death from any cause, whichever occurs first (3 years, 11 months).
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Months
        median (confidence interval 95%)
    5.5 (5.3 to 5.7)
    No statistical analyses for this end point

    Secondary: Objective response rate (ORR)

    Close Top of page
    End point title
    Objective response rate (ORR)
    End point description
    Objective response rate (ORR), is defined as the percentage of patients who attain complete response (CR) or partial response (PR) according to RECIST v1.
    End point type
    Secondary
    End point timeframe
    3 years 11 months.
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Percentage of participants
    number (confidence interval 95%)
        Percentage of responders
    72.3 (64.7 to 78.7)
        Percentage of non-responders
    27.7 (21.3 to 35.3)
    No statistical analyses for this end point

    Secondary: Duration of Response (DOR)

    Close Top of page
    End point title
    Duration of Response (DOR)
    End point description
    Duration of response (DOR), defined as the time from initial response to disease progression or death among patients who have experienced a CR or PR (unconfirmed) during the study. Duration of response will be calculated based on disease status evaluated by the investigator according to RECIST v1.1.
    End point type
    Secondary
    End point timeframe
    3 years 11 months.
    End point values
    Atezolizumab + Carboplatin + Etoposide
    Number of subjects analysed
    155
    Units: Months
    median (confidence interval 95%)
        Median DOR
    4.2 (4.1 to 4.5)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study treatment to 4 weeks after last dose of study treatment (3 years, 11 months).
    Adverse event reporting additional description
    AEs were reported for the safety population, defined as all those who received ≥1 dose of study treatment. There was one participant who withdrew from the study before receiving study treatment.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    26.0
    Reporting groups
    Reporting group title
    Atezolizumab + Carboplatin + Etoposide
    Reporting group description
    Participants who received treatment until disease progression per RECIST v1.1, unacceptable toxicity, or symptomatic deterioration attributed to disease progression as determined by the investigator.

    Serious adverse events
    Atezolizumab + Carboplatin + Etoposide
    Total subjects affected by serious adverse events
         subjects affected / exposed
    59 / 154 (38.31%)
         number of deaths (all causes)
    120
         number of deaths resulting from adverse events
    6
    Vascular disorders
    Arterial thrombosis
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Inferior vena cava syndrome
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Chest pain
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Non-cardiac chest pain
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    4 / 154 (2.60%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Pulmonary oedema
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Pneumonitis
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Investigations
    White blood cell count decreased
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Platelet count decreased
         subjects affected / exposed
    3 / 154 (1.95%)
         occurrences causally related to treatment / all
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    Neutrophil count decreased
         subjects affected / exposed
    4 / 154 (2.60%)
         occurrences causally related to treatment / all
    4 / 4
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Spinal fracture
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Fall
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Bradycardia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac failure
         subjects affected / exposed
    2 / 154 (1.30%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 2
    Myocardial infarction
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Supraventricular tachycardia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Atrial fibrillation
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Dysarthria
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cognitive disorder
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebrovascular accident
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Ataxia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Encephalitis autoimmune
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Paraesthesia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Spinal cord compression
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Syncope
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Pancytopenia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Neutropenias
         subjects affected / exposed
    13 / 154 (8.44%)
         occurrences causally related to treatment / all
    13 / 13
         deaths causally related to treatment / all
    0 / 0
    Leukopenia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    2 / 154 (1.30%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Diplopia
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Abdominal pain upper
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Constipation
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Diarrhoea
         subjects affected / exposed
    2 / 154 (1.30%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 1
    Hepatobiliary disorders
    Hepatic failure
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Renal failure
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Acute kidney injury
         subjects affected / exposed
    3 / 154 (1.95%)
         occurrences causally related to treatment / all
    3 / 3
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Staphylococcal infections
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Soft tissue infection
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Sepsis
         subjects affected / exposed
    2 / 154 (1.30%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    2 / 154 (1.30%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    1 / 1
    Lung abscess
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urinary tract infection
         subjects affected / exposed
    3 / 154 (1.95%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Hyponatraemia
         subjects affected / exposed
    4 / 154 (2.60%)
         occurrences causally related to treatment / all
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    Diabetic complication
         subjects affected / exposed
    1 / 154 (0.65%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Atezolizumab + Carboplatin + Etoposide
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    130 / 154 (84.42%)
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    8 / 154 (5.19%)
         occurrences all number
    8
    Platelet count decreased
         subjects affected / exposed
    15 / 154 (9.74%)
         occurrences all number
    19
    Nervous system disorders
    Dysgeusia
         subjects affected / exposed
    8 / 154 (5.19%)
         occurrences all number
    8
    Blood and lymphatic system disorders
    Leukopenia
         subjects affected / exposed
    9 / 154 (5.84%)
         occurrences all number
    13
    Anaemia
         subjects affected / exposed
    55 / 154 (35.71%)
         occurrences all number
    70
    Thrombocytopenia
         subjects affected / exposed
    18 / 154 (11.69%)
         occurrences all number
    30
    Neutropenia
         subjects affected / exposed
    43 / 154 (27.92%)
         occurrences all number
    60
    General disorders and administration site conditions
    Fatigue
         subjects affected / exposed
    17 / 154 (11.04%)
         occurrences all number
    18
    Pyrexia
         subjects affected / exposed
    35 / 154 (22.73%)
         occurrences all number
    40
    Asthenia
         subjects affected / exposed
    49 / 154 (31.82%)
         occurrences all number
    66
    Gastrointestinal disorders
    Vomiting
         subjects affected / exposed
    9 / 154 (5.84%)
         occurrences all number
    11
    Nausea
         subjects affected / exposed
    20 / 154 (12.99%)
         occurrences all number
    30
    Dyspepsia
         subjects affected / exposed
    8 / 154 (5.19%)
         occurrences all number
    8
    Diarrhoea
         subjects affected / exposed
    18 / 154 (11.69%)
         occurrences all number
    25
    Constipation
         subjects affected / exposed
    16 / 154 (10.39%)
         occurrences all number
    23
    Abdominal pain upper
         subjects affected / exposed
    8 / 154 (5.19%)
         occurrences all number
    8
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    14 / 154 (9.09%)
         occurrences all number
    17
    Dyspnoea
         subjects affected / exposed
    14 / 154 (9.09%)
         occurrences all number
    15
    Skin and subcutaneous tissue disorders
    Pruritus
         subjects affected / exposed
    12 / 154 (7.79%)
         occurrences all number
    14
    Alopecia
         subjects affected / exposed
    11 / 154 (7.14%)
         occurrences all number
    11
    Endocrine disorders
    Hypothyroidism
         subjects affected / exposed
    9 / 154 (5.84%)
         occurrences all number
    12
    Musculoskeletal and connective tissue disorders
    Pain in extremity
         subjects affected / exposed
    10 / 154 (6.49%)
         occurrences all number
    12
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    8 / 154 (5.19%)
         occurrences all number
    8

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    07 Apr 2020
    Updates to Title and Eligibility Criteria
    19 Apr 2021
    Inclusion of interim analysis
    23 Jun 2021
    Appendix 5 update according to atezolizumab IB
    31 Mar 2022
    Updates to Secondary Outcome Measures
    15 Mar 2023
    Updates to AESI and Risks Associated with Atezolizumab

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:18:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA